Lantheus Holdings Inc (STU:0L8)
€ 98.74 -1.96 (-1.95%) Market Cap: 7.38 Bil Enterprise Value: 7.25 Bil PE Ratio: 18.94 PB Ratio: 7.81 GF Score: 89/100

Lantheus Holdings, Inc., Progenics Pharmaceuticals, Inc. - M&A Call Transcript

Oct 02, 2019 / 12:00PM GMT
Release Date Price: €22
Operator

Good morning, and welcome to Lantheus Holdings and Progenics conference call regarding Lantheus' agreement to acquire Progenics. I'd like to remind everyone that a supplementary presentation will be used during today's call, which can be downloaded from a dedicated transaction website, www.lantheusprogenics.transactionannouncement.com.

Now I'd like to turn the call over to Mark Kinarney, Director of Investor Relations at Lantheus.

Mark Richard Kinarney
Lantheus Holdings, Inc. - Director of IR

Good morning, everyone. I would like to welcome everyone to our joint Lantheus Holdings and Progenics conference call regarding Lantheus' agreement to acquire Progenics. Joining me on the call today are Mary Anne Heino, Lantheus Holdings' President and CEO; Bob Marshall, Lantheus Holdings' CFO and Treasurer; Mark Baker, CEO of Progenics; and Pat Fabbio, Executive Vice President and CFO of Progenics.

This morning, we issued a press release announcing that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot